|
1）Li WC, Wang MR, Kong LB, et al. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC infectious diseases. 2011; 11: 165
|
|
|
|
2）Yang YF, Zhao W, Zhong YD, et al. Interferon therapy in chronic hepatitis B reduces pro-gression to cirrhosis and hepatocellular carci-noma: a meta-analysis. J Viral Hepat. 2009; 16: 265-71
|
|
|
|
|
3）Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012; 142: 1360-8 e1
|
|
|
|
|
|
4）Hepatitis B vaccines. Wkly Epidemiol Rec. 2004; 79: 255-63
|
|
|
|
|
|
5）Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008; 28: 1067-77
|
|
|
|
|
|
6）Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351: 1521-31
|
|
|
|
|
|
7）Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepato-cellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res. 2005; 32: 173-84
|
|
|
|
|
8）Papatheodoridis GV, Lampertico P, Manolako-poulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010; 53: 348-56
|
|
|
|
|
|
9）Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006; 119: 71 e9-16
|
|
|
|
|
|
10）Matsumoto A, Tanaka E, Morita S, et al. Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection. J Gastroenterol. 2012
|
|
|
|
|
|
11）Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010; 51: 1531-7
|
|
|
|
|
|
12）Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepato-cellular carcinoma. Gastroenterology. 2008; 135: 1192-9
|
|
|
|
|
|
13）Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012; 142: 1140-9 e3
|
|
|
|
|